Compare AX & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AX | LNTH |
|---|---|---|
| Founded | 1999 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.4B |
| IPO Year | 2005 | 2015 |
| Metric | AX | LNTH |
|---|---|---|
| Price | $85.71 | $67.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $97.07 | $77.33 |
| AVG Volume (30 Days) | 284.9K | ★ 1.0M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.44 | 2.39 |
| Revenue | $1,202,571,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $16.70 | $0.01 |
| Revenue Next Year | $9.76 | $1.24 |
| P/E Ratio | ★ $11.48 | $27.84 |
| Revenue Growth | ★ 6.69 | 1.95 |
| 52 Week Low | $54.46 | $47.25 |
| 52 Week High | $93.84 | $111.29 |
| Indicator | AX | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 61.46 | 73.27 |
| Support Level | $84.52 | $60.15 |
| Resistance Level | $86.87 | $64.40 |
| Average True Range (ATR) | 2.26 | 2.01 |
| MACD | 0.43 | 0.77 |
| Stochastic Oscillator | 80.39 | 97.42 |
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment. The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.